Report Publication Announcement • Oct 18, 2022
Report Publication Announcement
Open in ViewerOpens in native device viewer
Spexis AG / Key word(s): Conference
Spexis to present at BIO-Europe® 2022
18.10.2022 / 07:30 CET/CEST
Allschwil, Switzerland, October 18, 2022
Spexis to present at BIO-Europe ® 2022
Spexis AG (SIX: SPEX) today announced that the company will present and participate in one-on-one meetings at BIO-Europe ® , taking place October 24-26, 2022 in Leipzig, Germany, and virtually, November 2-4, 2022.
Jeff Wager, CEO of Spexis, will provide an overview of the company and its pipeline. The in-person presentation will be on Tuesday, October 25 th from 13:30 to 13:45 CEST in Multi-purpose Room 4. Jeff Wager and Stephan Wehselau, COO, will both be available to participate in one-on-one meetings. To schedule a meeting with the company, please use PartneringONE ® , the conference partnering system.
For further information please contact:
| For Investors: | For Media: |
| Hernan Levett Chief Financial Officer Spexis AG. +41 61 567 16 00 [email protected] |
Dr. Stephan Feldhaus Feldhaus & Partner +41 79 865 92 56 [email protected] |
| Europe Raimund Gabriel MC Services [email protected] Ph: +49 89 210 228 0 |
Dr. Brigitte Keller/Laurie Doyle MC Services [email protected] Europe: +49 89 210 228 0 U.S.: +1 339 832 0752 |
| U.S. Stephen Jasper Gilmartin Group [email protected] Ph. +1 858 525 2047 |
About Spexis
Spexis AG (SIX:SPEX) is a clinical-stage, publicly listed biopharmaceutical company. The company is focused on discovering and developing first-in-class macrocyclic molecules for rare diseases and cancers. The most advanced of four clinical candidates is ColiFin ® , an inhaled therapeutic for cystic fibrosis. ColiFin ® is already approved and marketed in Europe and is planned to enter global pivotal Phase 3 testing in early 2023 subject to financing. Furthermore, Spexis is applying its leading macrocyclic technology platform, the result of more than 25 years and $400 million of cumulative research and investment, to discover promising therapeutic candidates that can target difficult-to-drug structures. With a pipeline of potentially transformative product candidates, Spexis aims to deliver substantial benefits to patients and meaningful value to society and its stakeholders. For further information, please visit: www.spexisbio.com .
Disclaimer
This press release contains forward-looking statements which are based on current assumptions and forecasts of Spexis management. Known and unknown risks, uncertainties, and other factors could lead to material differences between the forward-looking statements made here and the actual development, in particular Spexis' results, financial situation, and performance. Readers are cautioned not to put undue reliance on forward-looking statements, which speak only as of the date of this communication. Spexis disclaims any intention or obligation to update and revise any forward-looking statements, whether as a result of new information, future events or otherwise.
End of Media Release
| Language: | English |
| Company: | Spexis AG |
| Hegenheimermattweg 125 | |
| 4123 Allschwil | |
| Switzerland | |
| Phone: | +41 61 567 1600 |
| Fax: | +41 61 567 1601 |
| E-mail: | [email protected] |
| Internet: | www.spexisbio.com |
| ISIN: | CH0106213793 |
| Valor: | SPEX |
| Listed: | SIX Swiss Exchange |
| EQS News ID: | 1465411 |
| End of News | EQS News Service |
1465411 18.10.2022 CET/CEST
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.